
Building Interprofessional Frameworks to Improve Diagnostic and Treatment Paradigms for Patients with Lower-Risk MDS
Greenwood, SC US
November 24, 2025
Self Regional Healthcare
Patients with myelodysplastic syndromes/myelodysplastic neoplasms (MDS) experience significant symptom burden including anemia-related symptoms, problems with physical functioning and dyspnea, fatigue, pain, discomfort, and restricted mobility that, in an older population can contribute to overall frailty and vulnerability. In addition, patients with lower-risk MDS (LR-MDS) are often dependent on regular red blood cell (RBC) transfusions to help manage symptoms of anemia; however, transfusion dependency is extremely burdensome for patients, further affecting their quality of life (QoL).
Despite this, MDS continues to be underrecognized and even with novel and emerging therapeutic options, significant delays in diagnosis persist, delaying treatment initiation and negatively affecting patient outcomes. Reducing the time to diagnosis and improving individualized treatment of lower risk LR-MDS requires a collaborative, interprofessional team that will all work together to improve diagnosis, risk stratification, molecular testing, optimal and individualized treatment, and enhanced symptom management.
Using expert-developed, peer-reviewed content, specialists at cancer centers will facilitate a 1-hour learning and action planning program with their clinical team to interpret the latest evidence, enhance their treatment regimens, and establish multidisciplinary practices to improve the delivery of personalized medicine for patients with LR-MDS.
Educational Partner: Academy for Continued Healthcare Learning (ACHL)
Commercial Support: Support for this activity has been provided through an educational grant from Geron Corporation.
Commercial Support: Support for this activity has been provided through an educational grant from Geron Corporation.
Target Audience
This educational activity is designed for hematologists/oncologists, pathologists, advanced practice providers and nurses in hematology practice, internists, primary care physicians, clinical/oncology pharmacists, and other members of the multidisciplinary team.
Learning Objectives
Upon completion of this activity, learners will be able to:
- Integrate evidence-based approaches to support earlier, more accurate diagnosis and classification of myelodysplastic syndromes (MDS)
- Develop clinical frameworks to distinguish patient- and disease-related factors that affect risk stratification
- Individualize treatment selection for patients with LR-MDS considerate of latest evidence around novel and emerging therapies
- Develop clinical pathways to facilitate patient-clinician communication and ongoing multidisciplinary care for patients with LR-MDS
Event starts:
11/24/2025 - 1:00pm
Event ends:
11/24/2025 - 2:00pm
Activity opens:
11/24/2025
Activity expires:
02/19/2026
Add to calendar:
Self Regional Healthcare
1325 Spring St
Greenwood, SC
29646
United States

WANT TO KNOW MORE?
Visit the Academy for Continued Healthcare Learning (ACHL) website!
ACCESSIBILITY The University of Chicago is committed to providing equal access appropriate to need and circumstances and complies fully with legal requirements of the Americans with Disabilities Act. If you are in need of special accommodation, please contact our office at https://www.achlcme.org/.
The University of Chicago reserves the right to cancel or postpone this conference due to unforeseen circumstances. In the unlikely event this activity must be cancelled or postponed, the registration fee will be refunded; however, The University of Chicago is not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.
FACULTY
Anand Patel, MDAssistant Professor of Medicine, Section of Hematology/Oncology
Medical Director, Inpatient Leukemia Service, Hematology-Oncology
University of Chicago
Chicago, IL
Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Chicago Pritzker School Of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
REGISTRATION: For more information, visit the ACHL website or click the button below!
Please login or create an account to proceed.

Facebook
X
LinkedIn
Forward

